U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. Drug Databases
  3. Drug Shortages

FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Report a Drug Shortage | FAQ | Background Info | Get Email Alerts | Download Current Drug Shortages | Contact Us

Start Over | Back to Previous Screen

Gemcitabine Hydrochloride Injection
Status: Discontinuation
»Therapeutic Categories: Oncology

Expand all

Hospira, Inc., a Pfizer Company (New 09/11/2025)

Company Contact Information:
844-646-4398

Presentation Posting Date Related Information
Gemcitabine Hydrochloride, Injection, 1 g/26.3 mL (38 mg/mL), sterile solution in a single-dose glass vial NovaPlus (NDC 0409-0181-25) 09/11/2025 Discontinuation of the manufacture of the drug
Gemcitabine Hydrochloride, Injection, 2 g/52.6 mL (38 mg/mL), sterile solution in a single-dose glass vial NovaPlus (NDC 0409-0182-25) 09/11/2025 Discontinuation of the manufacture of the drug
Gemcitabine Hydrochloride, Injection, 200 mg/5.26 mL (38 mg/mL), sterile solution in a single-dose glass vial NovaPlus (NDC 0409-0183-25) 09/11/2025 Discontinuation of the manufacture of the drug
Back to Top